Included in the formulation
АТХ:D.06.B.A Sulfonamides
Pharmacodynamics:The chemical structure of the drug is similar to para-aminobenzoic acid, involved in the synthesis of folic acid, without which the growth of microorganisms ceases. Competitively inhibits dihydropteroate synthetase, and also prevents the inclusion of para-aminobenzoic acid in dihydrophosphate. Violation of the synthesis of dihydrofolic acid reduces the formation of tetrahydrofolic acid from it, which is necessary for the synthesis of purine and pyrimidine bases. As a result, the synthesis of nucleic acids is suppressed, which leads to inhibition of growth and reproduction of microorganisms.
It does not break the structure of the cells of the macroorganism, since they already recycle the already prepared dihydrofolic acid. The content of para-aminobenzoic acid increases in purulent discharge, therefore the effectiveness of the drug is reduced.
Pharmacokinetics:The drug for topical application does not have a systemic effect on the body.
Indications:It is used to treat postoperative wounds after opening abscesses and phlegmon, with burns, bedsores, trophic ulcers,to eliminate purulent infection with dermatitis and pyoderma.
I.A30-A49.A46 Erys
XII.L00-L08 Infections of the skin and subcutaneous tissue
XII.L00-L08.L08.0 Pyoderma
XII.L80-L99.L87 Transepidermal perforated changes
XIX.T79.T79.3 Post-traumatic wound infection, not elsewhere classified
Contraindications:Anemia, leukemia, hepatic and renal insufficiency, porphyria, congenital deficiency of glucose-6-phosphate dehydrogenase, individual intolerance, children's age up to 3 months.
Carefully:It is used with caution in acute renal failure, under the control of blood tests. With allergy to sulfonamides, there is a danger of developing the Lyell syndrome. With systemic lupus erythematosus and bronchial asthma, there are possible exacerbations of diseases, hypersensitivity.
Pregnancy and lactation:Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.
Dosing and Administration:Higher daily doses for children:
Up to 1 year, 12 g (0.6 g of mesulfamide);
1-5 years - 36 g (1.8 g of mesulfamide);
5-12 years - 60 g (3 g of mesulfamide).
Adultse
The treatment requires washing the wound surface with a solution of 3% hydrogen peroxide or 0.05% chlorhexidine, after which Liniment is applied in a thin layer and covered with acea bandage bandage.The dressing of purulent wounds is performed twice a day. With burns - 1 time per day.
Treatment of skin purulent diseases lasts for 1-3 weeks.
The highest daily dose: 120 g of liniment (6 g of mesulfamide).
Side effects:Hemopoietic system: aplastic anemia.
Digestive system: hepatitis.
Dermatological reactions: photosensitivity, rash.
Urinary system: interstitial nephritis, hematuria.
Allergic reactions.
Overdose:Oppression of leukopoiesis: agranulocytosis, leukopenia. As a consequence, the development of immunodeficiency state.
Treatment: symptomatic, after drug withdrawal.
Interaction:With the simultaneous use of novocain and anesthesin, the effect of the drug is weakened by the fact that the anesthetics hydrolyze with the release of a large amount of para-aminobenzoic acid.
Special instructions:The drug is used to treat postoperative purulent wounds and trophic skin disorders, as well as burns.Liniment containing mesulfamide, is effective only when applied to the surface of the wound, cleared from tissue detritus and pus.